NASDAQ:HALO

Halozyme Therapeutics Stock Forecast, Price & News

$46.20
+0.25 (+0.54 %)
(As of 04/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$45.82
Now: $46.20
$47.12
50-Day Range
$39.51
MA: $43.18
$51.45
52-Week Range
$17.81
Now: $46.20
$56.40
Volume887,912 shs
Average Volume1.40 million shs
Market Capitalization$6.62 billion
P/E Ratio288.75
Dividend YieldN/A
Beta1.77
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its proprietary product include Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company is also developing Perjeta for breast cancer; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ALXN1210 and ALXN1810 subcutaneous formulations; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; and Centre for the AIDS Programme of Research in South Africa. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.
Halozyme Therapeutics logo

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:HALO
CUSIP40637H10
Phone858-794-8889
Employees136
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$195.99 million
Book Value$0.63 per share

Profitability

Net Income$-72,240,000.00

Miscellaneous

Market Cap$6.62 billion
Next Earnings Date5/10/2021 (Estimated)
OptionableOptionable

Headlines

Would Halozyme Make a Good Warren Buffett Stock?
April 4, 2021 |  finance.yahoo.com
HALO Jan 2022 30.000 put
March 28, 2021 |  uk.finance.yahoo.com
HALO Apr 2021 42.000 call
March 28, 2021 |  uk.finance.yahoo.com
First Week of HALO May 21st Options Trading
March 21, 2021 |  nasdaq.com
Halozyme Stock Joins The 80-Plus RS Rating Club
March 17, 2021 |  finance.yahoo.com
Let's Take Another Look at Halozyme Therapeutics
March 4, 2021 |  finance.yahoo.com
2 Overvalued Biotech Stocks Still Worth Buying
March 4, 2021 |  finance.yahoo.com
See More Headlines

MarketRank

Overall MarketRank

1.54 out of 5 stars

Medical Sector

458th out of 2,021 stocks

Biological Products, Except Diagnostic Industry

66th out of 177 stocks

Analyst Opinion: 1.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -
$46.20
+0.25 (+0.54 %)
(As of 04/15/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive HALO News and Ratings via Email

Sign-up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Halozyme Therapeutics (NASDAQ:HALO) Frequently Asked Questions

Is Halozyme Therapeutics a buy right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Halozyme Therapeutics in the last twelve months. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Halozyme Therapeutics stock.
View analyst ratings for Halozyme Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Halozyme Therapeutics?

Wall Street analysts have given Halozyme Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Halozyme Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Halozyme Therapeutics?

Halozyme Therapeutics saw a decline in short interest in the month of March. As of March 15th, there was short interest totaling 8,280,000 shares, a decline of 33.3% from the February 28th total of 12,420,000 shares. Based on an average trading volume of 1,410,000 shares, the short-interest ratio is currently 5.9 days. Approximately 6.3% of the company's stock are sold short.
View Halozyme Therapeutics' Short Interest
.

When is Halozyme Therapeutics' next earnings date?

Halozyme Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, May 10th 2021.
View our earnings forecast for Halozyme Therapeutics
.

How were Halozyme Therapeutics' earnings last quarter?

Halozyme Therapeutics, Inc. (NASDAQ:HALO) released its quarterly earnings results on Tuesday, February, 23rd. The biopharmaceutical company reported $0.50 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.56 by $0.06. The biopharmaceutical company had revenue of $121.70 million for the quarter, compared to analyst estimates of $120.75 million. Halozyme Therapeutics had a net margin of 10.78% and a trailing twelve-month return on equity of 24.29%. The business's revenue for the quarter was up 126.6% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.24) EPS.
View Halozyme Therapeutics' earnings history
.

How has Halozyme Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Halozyme Therapeutics' stock was trading at $18.22 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, HALO stock has increased by 153.6% and is now trading at $46.20.
View which stocks have been most impacted by COVID-19
.

What guidance has Halozyme Therapeutics issued on next quarter's earnings?

Halozyme Therapeutics updated its FY21 earnings guidance on Tuesday, February, 23rd. The company provided earnings per share (EPS) guidance of $1.40-1.55 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.58. The company issued revenue guidance of $375-395 million, compared to the consensus revenue estimate of $389.15 million.

What price target have analysts set for HALO?

10 brokerages have issued 12-month price objectives for Halozyme Therapeutics' stock. Their forecasts range from $23.00 to $65.00. On average, they expect Halozyme Therapeutics' share price to reach $42.92 in the next year. This suggests that the stock has a possible downside of 7.1%.
View analysts' price targets for Halozyme Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Halozyme Therapeutics' key executives?

Halozyme Therapeutics' management team includes the following people:
  • Dr. Helen I. Torley, Pres, CEO & Director (Age 58, Pay $1.52M)
  • Ms. Elaine D. Sun, Sr. VP & CFO (Age 49, Pay $859.58k)
  • Dr. Michael J. LaBarre, Sr. VP & Chief Technical Officer (Age 57, Pay $710.18k)
  • Mr. Masaru Matsuda Esq., Sr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 50, Pay $707.84k)
  • Mr. Ed Gemo, VP, Chief Information & Security Officer
  • Mr. Albert S. Kildani, VP of Investor Relations & Corp. Communications
  • Ms. Amy Marinne Fox, VP of HR
  • Mr. William J. Fallon, Sr. VP &, Global ENHANZE Program Lead, CMC Operations & Strategic Alliances (Age 64)
  • Dr. Steve Knowles, Chief Medical Officer
  • Mr. Todd Butler, Chief of Staff to the CEO, VP & Head of Project Management

What is Helen Torley's approval rating as Halozyme Therapeutics' CEO?

12 employees have rated Halozyme Therapeutics CEO Helen Torley on Glassdoor.com. Helen Torley has an approval rating of 75% among Halozyme Therapeutics' employees.

Who are some of Halozyme Therapeutics' key competitors?

What other stocks do shareholders of Halozyme Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Halozyme Therapeutics investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Micron Technology (MU), Gilead Sciences (GILD), Athabasca Oil (ATH), NIC (EGOV), Allergan (AGN) and AbbVie (ABBV).

What is Halozyme Therapeutics' stock symbol?

Halozyme Therapeutics trades on the NASDAQ under the ticker symbol "HALO."

Who are Halozyme Therapeutics' major shareholders?

Halozyme Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Scout Investments Inc. (0.23%), Retirement Systems of Alabama (0.12%), Louisiana State Employees Retirement System (0.02%), Crossmark Global Holdings Inc. (0.01%), State of Alaska Department of Revenue (0.01%) and Pacer Advisors Inc. (0.01%). Company insiders that own Halozyme Therapeutics stock include Connie Matsui, Dimitrios Chondros, Helen Torley, James M Daly, Jeffrey William Henderson, Kenneth J Kelley and Michael J Labarre.
View institutional ownership trends for Halozyme Therapeutics
.

Which institutional investors are selling Halozyme Therapeutics stock?

HALO stock was sold by a variety of institutional investors in the last quarter, including Hexavest Inc., and State of Alaska Department of Revenue. Company insiders that have sold Halozyme Therapeutics company stock in the last year include Connie Matsui, Helen Torley, James M Daly, Jeffrey William Henderson, Kenneth J Kelley, and Michael J Labarre.
View insider buying and selling activity for Halozyme Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Halozyme Therapeutics stock?

HALO stock was acquired by a variety of institutional investors in the last quarter, including Scout Investments Inc., Pacer Advisors Inc., EFG Asset Management Americas Corp., Louisiana State Employees Retirement System, Retirement Systems of Alabama, Crossmark Global Holdings Inc., and Veriti Management LLC.
View insider buying and selling activity for Halozyme Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Halozyme Therapeutics?

Shares of HALO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Halozyme Therapeutics' stock price today?

One share of HALO stock can currently be purchased for approximately $46.20.

How much money does Halozyme Therapeutics make?

Halozyme Therapeutics has a market capitalization of $6.62 billion and generates $195.99 million in revenue each year. The biopharmaceutical company earns $-72,240,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis.

How many employees does Halozyme Therapeutics have?

Halozyme Therapeutics employs 136 workers across the globe.

What is Halozyme Therapeutics' official website?

The official website for Halozyme Therapeutics is www.halozyme.com.

Where are Halozyme Therapeutics' headquarters?

Halozyme Therapeutics is headquartered at 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA, 92121-1345.

How can I contact Halozyme Therapeutics?

Halozyme Therapeutics' mailing address is 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA, 92121-1345. The biopharmaceutical company can be reached via phone at 858-794-8889 or via email at [email protected]


This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.